Table 1.

Patients, disease and tumor characteristics

All cases:	76
Age
N cases	76
Mean ± SD	57.2 ± 15.4
Median	57.2
Min-max	30-87.5
	N (%)
Disease presentation
N cases	76
Concurrent	52 (68.4)
Metachronous	24 (31.6)
Menopausal status
N cases	71
Pre	25 (40)
Post	46 (60)
	SIDE 1	SIDE 2	TOTAL
Positive nodes
N cases	60	51	111
Mean ± SD	3.1 ± 5.8	1.1 ± 1.9	2.5 ± 3.0
Median	0	0.5	0
Min-max	0-23	0-9	0-23
Tumor size
N cases	71	70	141
Mean ± SD	2.3 ± 1.9	2.5 ± 3.0	2.4 ± 2.5
Median	1.8	1.8	1.8
Min-max	0.1-11	0.2-21	0.1-21
Ki67
N cases	68	68	136
Mean ± SD	26.6 ± 25.4	29 ± 24.5	27.9 ± 24.8
Median	18	23	20
Min-max	1-90	1-95	1-95
Tumor infiltrating lymphocytes (TILs)
N cases	68	63	131
Mean ± SD	9.5 ± 15.5	11.1 ± 17.2	10.3 ± 16.3
Median	3	4	3
Min-max	1-75	1-80	1-80
	SIDE 1	SIDE 2	TOTAL
	N	%	N	%	N	%
Main lesion, carcinoma
In situ	7	9.2	7	9.3	14	9.2
Invasive	69	90.8	68	90.7	137	90.8
Concordance* invasive ca: 64/75 (85.3%)
Histology
Ductal, NST	51	67.1	48	64	99	65.1
Other	25	32.9	27	36	52	34.9
Concordance histology: 44/75 (61.3%)
Grade
I	11	15.7	8	11.9	19	13.9
II	27	39.7	27	39.7	54	39.4
III	32	45.7	32	47.8	64	46.7
Concordance grade: 37/63 (58.7%)
In situ lesion
Present	47	61.2	43	57.3	90	59.6
Absent	29	38.2	32	42.7	61	40.4
Concordance in situ presence: 39/76 (51.3%)
Clinical subtype
HER2-Enriched	5	6.9	3	4.2	8	5.5
Luminal A	34	45.9	31	43.1	65	44.5
Luminal B	21	28	21	29.2	42	28.8
Luminal-HER2	5	6.8	8	11.1	13	8.9
TNBC	9	12.2	9	12.5	18	12.3
Concordance, clinical subtype: 37/72 (51.4%)
TILs
Low (≤5%)	50	73.6	41	65.1	91	69.5
High (5-50%)	16	23.5	19	30.1	35	26.7
LPBC (>50%)	2	2.9	3	4.8	5	3.8
Concordance, TILs: 43/59 (72.9%)
Multifocality
No	54	72	49	67.1	103	69.6
Yes	21	28	24	32.9	45	30.4
Concordance, multifocality: 48/72 (66.7%)
Size, categorical
<2 cm	38	52.1	42	59.3	80	55.5
≥2 cm	35	47.9	29	39.7	64	44.5
Concordance, size: 36/69 (52.2%)
Nodal status
0-3 LN	49	80.3	46	90.2	95	84.8
≥4 LN	12	19.7	5	0.8	17	15.2
Concordance, nodal status: 35/44 (79.5%)

^*concordance between Side 1 and Side 2.